Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review

Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review

Abstract Background Immune checkpoint inhibitors (ICPIs) have changed the way advanced malignancies are currently confronted, improving cancer patients’ outcomes but also generating distinct immune-related (ir) adverse events. ICPIs-induced colitis is a common complication showing different clinical...

Full description

Bibliographic Details
Main Authors:	Stratigoula Sakellariou, Dionysia N. Zouki, Dimitrios C. Ziogas, Despoina Pouloudi, Helen Gogas, Ioanna Delladetsima
Format:	Article
Language:	English
Published:	BMC 2021-05-01
Series:	BMC Gastroenterology
Subjects:	Immune checkpoint inhibitors-related colitis Immune checkpoint inhibitors-related adverse events Intracryptal granulomas Granulomatous colitis Ipilimumab-related granulomas
Online Access:	https://doi.org/10.1186/s12876-021-01812-7

Similar Items

Ipilimumab-induced renal granulomatous arteritis: a case report
by: Mathilde Lemoine, et al.
Published: (2019-10-01)

Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
by: Carmen Portenkirchner, et al.
Published: (2021-04-01)

Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma
by: Maria Paparoupa, et al.
Published: (2020-10-01)

Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor
by: Marta Rocha, et al.
Published: (2018-12-01)

Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
by: Jean R. Kuo, et al.
Published: (2018-11-01)

The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review
by: Ryosuke Yamauchi, et al.
Published: (2018-08-01)

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
by: Hamzah Abu-Sbeih, et al.
Published: (2018-09-01)

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
by: Yinghong Wang, et al.
Published: (2018-05-01)

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
by: Hamzah Abu-Sbeih, et al.
Published: (2018-12-01)

Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors
by: Carlos Eduardo de Andrea, et al.
Published: (2020-01-01)

Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report
by: Masood Sadaat, et al.
Published: (2018-06-01)

Immune checkpoint inhibitors‐induced eosinophilic pneumonia: A case report
by: Kanako Hara, et al.
Published: (2021-03-01)

Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma
by: Yuan Liu, et al.
Published: (2019-12-01)

Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review
by: Nabil E. Omar, et al.
Published: (2020-10-01)

A case of checkpoint inhibitor-induced celiac disease
by: Dana Alsaadi, et al.
Published: (2019-08-01)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
by: Abdulaali R. Almutairi, et al.
Published: (2020-02-01)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01)

Neurosarcoidosis following Immune Checkpoint Inhibition
by: Anastasie M. Dunn-Pirio, et al.
Published: (2018-07-01)

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
by: Hamzah Abu-Sbeih, et al.
Published: (2019-04-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
by: Hanping Wang, et al.
Published: (2020-01-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
by: Eva Zhang, et al.
Published: (2021-05-01)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01)

Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
by: Anna Carbó-Bagué, et al.
Published: (2021-09-01)

Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor
by: Hanping WANG, et al.
Published: (2019-10-01)

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
by: Vincenzo Quagliariello, et al.
Published: (2020-10-01)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
by: I. Puzanov, et al.
Published: (2017-11-01)

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
by: Florian Huemer, et al.
Published: (2021-01-01)

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
by: Hamzah Abu-Sbeih, et al.
Published: (2019-09-01)

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
by: Daniel H Johnson, et al.
Published: (2018-10-01)

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
by: Yoko Maegawa, et al.
Published: (2020-09-01)

Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report
by: Angela Damato, et al.
Published: (2021-06-01)

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
by: Omid Kooshkaki, et al.
Published: (2020-06-01)

Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review
by: Agnese Barnabei, et al.
Published: (2020-12-01)

Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks
by: Giuseppe Fanciulli, et al.
Published: (2021-12-01)

Associated Myocarditis: A Predictive Factor for Response?
by: Walid Shalata, et al.
Published: (2020-05-01)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
by: Chiao-En Wu, et al.
Published: (2020-06-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management
by: Giuseppe Fanciulli, et al.
Published: (2021-06-01)

A Review of Immune-Mediated Adverse Events in Melanoma
by: Lucy Boyce Kennedy, et al.
Published: (2019-07-01)

Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study
by: Liz Jamieson, et al.
Published: (2020-08-01)